Matrix biology of abdominal aortic aneurysms in diabetes: Mechanisms underlying the negative association

Connective Tissue Research

Volumn 48, Issue 3, 2007, Pages 125-131

  Norman, Paul E ^a   Davis, Timothy M E ^b   Le, Max Tan Quoc ^a   Golledge, Jonathan ^c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c JAMES COOK UNIVERSITY   (Australia)

Author keywords

Abdominal Aortic Aneurysm; Diabetes; Extracellular Matrix

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; AMINOGUANIDINE; ANGIOTENSIN II; COLLAGENASE 3; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ELASTIN; GELATINASE A; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROPHAGE ELASTASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PYRIDOXAMINE; STROMELYSIN; STRUCTURAL PROTEIN;

ABDOMINAL AORTA ANEURYSM; AORTA WALL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; ENZYME DEGRADATION; ENZYME SYNTHESIS; FIBRINOLYSIS; GENE LOCATION; HUMAN; HYPERTENSION; INFLAMMATION; MEDICAL RESEARCH; MOLECULAR MECHANICS; PROTEIN DEPLETION; RISK ASSESSMENT; SHORT SURVEY;

AORTIC ANEURYSM, ABDOMINAL; CARBOHYDRATE METABOLISM; DIABETES COMPLICATIONS; EXTRACELLULAR MATRIX; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 34249849049     PISSN: 03008207     EISSN: 16078438     Source Type: Journal    
DOI: 10.1080/03008200701331524     Document Type: Short Survey

References (89)

1. Lederle, F. A., Johnson, G. R., Wilson, S. E., Chute, E. P., Litooy, F. N., Bandyk, D., Krupski, W. C., Barone, G. W., Acher, C. W. and Ballard, D. J. (1997) Prevalence and associations of abdominal aortic aneurysm detected through screening. Ann. Int. Med., 126, pp. 441-449.
2. Blanchard, J. F. (1999) Epidemiology of abdominal aortic aneurysms. Epidemiol. Rev., 21, pp. 207-221.
3. Jamrozik, K., Norman, P. E., Spencer, C. A., Parsons, R. W., Tuohy, R., Lawrence-Brown, M. M. and Dickinson, J. A. (2000) Screening for abdominal aortic aneurysms: Lessons from a population-based study. Med. J. Aust., 173, pp. 345-350.
4. Shteinberg, D., Halak, M., Shapiro, S., Kinarty, A., Sobol, E., Lahat, N. and Karmeli, R. (2000) Abdominal aortic aneurysm and aortic occlusive disaese: A comparison of risk factors and inflammatory response. Eur. J. Vasc. Endovas. Surg., 20, pp. 462-465.
5. Blanchard, J., Armenian, H. and Friesen, P. (2000) Risk factors for abdominal aortic aneurysm: Results of a case-control study. Am. J. Epidemiol., 151, pp. 575-583.
6. Marian, A. (2001) On genetics, inflammation, and abdominal aortic aneurysm. Circulation, 103, pp. 2222-2224.
7. Eriksson, P., Jormsjo-Pettersson, S., Brady, A., Deguchi, H., Hamsten, A. and Powell, J. (2005) Genotype-phenotype relationships in an investigation of the role of proteases in abdominal aortic aneurysm expansion. Br. J. Surg., 92, pp. 1372-1376.
8. LaMorte, W. W., Scott, T. E. and Menzoian, J. O. (1995) Racial differences in the incidence of femoral bypass and abdominal aortic aneurysmectomy in Massachusetts: Relationship to cardiovascular risk factors. J. Vasc. Surg., 21, pp. 422-431.
9. Mattes, E., Davis, T. M.E., Yang, D., Ridley, D., Lund, H. and Norman, P. E. (1997) Prevalence of abdominal aortic aneurysms in men with diabetes. M.J.A., 166, pp. 630-634.
10. Brady, A. R., Thompson, S. G., Fowkes, G. R., Greenhalgh, R. M. and Powell, J. T. (2004) Abdominal aortic aneurysm expansion. Risk factors and time intervals for surveillance. Circulation, 110, pp. 16-21.
11. Norman, P. E., Spencer, C. A., Lawrence-Brown, M. M. and Jamrozik, K. (2004) C-reactive protein levels and the expansion of screen-detected abdominal aortic aneurysms in men. Circulation, 110, pp. 862-866.
12. Le, M. T.Q., Jamrozik, K., Davis, T. M.E. and Norman, P. (2007) Negative association between infra-renal aortic diameter and glycaemia: The health in men study. Eur. J. Vasc. Endovasc. Surg., 33, pp. 592-598.
13. Sakalihasan, N., Heyeres, A., Nusgens, B. V., Limet, R. and Lapiere, C. M. (1993) Modifications of the extracellular matrix of aneurysmal abdominal aortas as a function of their size. Eur. J. Vasc. Surg., 7, pp. 633-637.
14. Freestone, T., Turner, R. J., Coady, A., Higman, D. J., Greenhalgh, R. M. and Powell, J. T. (1995) Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler. Thromb. Vasc. Biol., 15, pp. 1145-1151.
15. Carrell, T. W.G., Burnand, K. G., Wells, G. M.A., Clements, J. M. and Smith, A. (2002) Stromelysin-1 (matrix metalloproteinase-3). and tissue inhibitor of metalloproteinase-3 are overexpressed in the wall of abdominal aortic aneurysms. Circulation, 105, pp. 477-482.
16. Curci, J. A., Liao, S., Huffman, M. D., Shapiro, S. D. and Thompson, R. W. (1998) Expression and localisation of macrophage elastase (matrix metalloproteinase-12) in abdominal aortic aneurysms. J. Clin. Invest., 102, pp. 1900-1910.
17. Thompson, R. W., Holmes, D. R., Mertens, R. A., Liao, S., Botney, M. D., Mecham, R. P., Welgus, H. G. and Parks, W. C. (1995) Production and localisation of 92-kilodalton gelatinase in abdominal aortic aneurysms. J. Clin. Invest., 96, pp. 318-326.
18. Sakalihasan, N., Delvenne, P., Nusgens, B. V., Limet, R. and Lapiere, C. M. (1996) Activated forms of MMP2 and MMP9 in abdominal aortic aneurysms. J. Vasc. Surg., 24, pp. 127-133.
19. Goodall, S., Crowther, M., Hemingway, D. M., Bell, P. R. and Thompson, M. M. (2001) Ubiquitous elevation of matrix metalloproteinase-2 expression in the vasculature of patients with abdominal aneurysms. Circulation., 104, pp. 304-309.
20. McMillan, W. D., Tamarina, N. T., Cipollone, M., Jonson, D. A., Parker, M. A. and Pearce, W. H. (1997) Size matters: The relationship between MMP-9 expression and aortic diameter. Circulation, 96, pp. 2228-2232.
21. Pyo, R., Lee, J. K., Shipley, J. M., Curci, J. A., Mao, D., Ziporin, S. J. and Ennis, T. L. (2000) Targeted gene disruption of metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J. Clin. Invest., 105, pp. 1641-1649.
22. Longo, G. M., Xiong, W., Greiner, T. C., Zhao, Y., Fiotti, N. and Baxter, B. T. (2002) Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J. Clin. Invest., 110, pp. 625-632.
23. Pearce, W. H. and Shively, V. P. (2006) Abdominal aortic aneurysm as a complex multifactorial disease. Interactions of polymorphisms of inflammatory genes, features of autoimmunity, and current status of MMPs. Ann. NY Acad. Sci., 1085, pp. 117-132.
24. Keulen, C. J. van Vlijmen-van, Vahl, A. C., Hennekam, R. C.M., Rauwerda, J. A. and Pals, G. (2003) Genetic linkage of candidate genes in families with abdominal aortic aneurysms?. Eur. J. Vasc. Endovas. Surg., 26, pp. 205-210.
25. Jones, G. T., Phillips, L. V., Harris, E. L., Rossaak, J. I. and van Rij, A. M. (2003) A functional matrix metalloproteinase 9 polymorphism (C-1562T). is associated with abdominal aortic aneurysm. J. Vasc. Surg., 38, pp. 1363-1367.
26. Jormsjo, S., Ye, S., Moritz, J., Walter, D. H., Dimmeler, S., Zeiher, A. M., Henney, A., Hamsten, A. and Eriksson, P. (2000) Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ. Res., 86, pp. 998-1003.
27. Mauer, S. (1994) Structural-functional correlations of diabetic nephropathy. Kidney Int., 45, pp. 612-622.
28. Jones, S. C., Saunders, H. J. and Pollock, C. A. (1999) High glucose increases growth and collagen synthesis in cultured human tubulointerstitial cells. Diabetic Med., 16, pp. 932-938.
29. Lam, S., Verhagen, N. A.M., Strutz, F., van der Pijl, J. W., Daha, M. R. and van Kooten, C. (2003) Glucose-induced fibronectin and collagen type III expression in renal fibroblasts can occur independent of TGF-β1. Kidney Int., 63, pp. 878-888.
30. Asbun, J., Manso, A. M. and Villareal, F. J. (2005) Profibrotic influence of high glucose concentration on cardiac fibroblast functions: effects of losartan and vitamin E. Am. J. Physiol. (Endocinol. Met.), 288, pp. H227-H234.
31. Singh, R., Alavi, N., Singh, A. K. and Leehey, D. (1999) Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes, 48, pp. 2066-2073.
32. Murphy, M., Godson, C., Cannon, S., Kato, S., Mackenzie, H. S., Martin, F. and Brady, H. R. (1999) Suppression subtraction hybridization identiefies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J. Biol. Chem., 274, pp. 5830-5834.
33. Twigg, S. M., Chen, M. M., Joly, A. H., Chakrapani, S. D., Tsubaki, J., Kinm, H.-S., Oh, Y. and Rosenfeld, R. G. (2001) Advanced blycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein-2). in human fibroblasts: a potential mechanism for expansion of extracellular matrix in diabetes mellitus. Endocinology, 142, pp. 1760-1769.
34. McLennan, S., Wang, X., Moreno, V., Yue, D. and Twigg, S. (2004) Connective tissue growth factor mediates high glucose effects on matrix degradation through tissue inhibitor of matrix metalloproteinase type 1: implications for diabetic nephropathy. Endocrinology, 145, pp. 5646-5655.
35. Death, A., Fisher, E., McGrath, K. and Yue, D. (2003) High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis., 168, pp. 263-269.
36. Uemura, S., Matsushita, H., Li, W., Glassford, A. J., Asagami, T., Lee, K.-H., Harrison, D. G. and Tsao, P. S. (2001) Diabetes mellitus enhances vascular matrix metalloproteinase activity. Role of oxidative stress. Circ. Res., 88, pp. 1291-1298.
37. Nakamura, T., Fukui, M., Ebihara, I., Osada, S., Tomino, Y. and Koide, H. (1994) Abnormal gene expression of matrix metalloproteinases and their inhibitor in glomeruli from diabetic rats. Renal Physiol. Biochem., 17, pp. 316-325.
38. Wu, K., Setty, S., Mauer, S. M., Killen, P., Nagase, H., Michael, A. F. and Tsibary, E. (1997) Altered kidney matrix gene expression in early stages of experimental diabetes. Acta Anatomica, 158, pp. 155-165.
39. Portik-Dobos, V., Anstadt, M. P., Hutchinson, J., Bannan, M. and Ergul, A. (2002) Evidence for matrix metalloproteinase induction/activation system in arterial vasculature and decreased synthesis and activity in diabetes. Diabetes, 51, pp. 3063-3068.
40. Prete, D. Del, Anglani, F., Forino, M., Ceol, M., Fioretto, P., Nosadini, R., Baggio, B. and Gambaro, G. (1997) Down-regulation of glomerular matrix metalloproteinase-2 gene in human NIDDM. Diabologia, 40, pp. 1449-1454.
41. McLennan, S., Kelly, D., Cox, A., Cao, Z., Lyons, J., Yue, D. and Gilbert, R. (2002) Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases. Diabetologia, 45, pp. 268-275.
42. Jesmin, S., Sakuma, I., YHattori, Y. and Kitabatake, A. (2003) Role of angiotensin II in altered expression of molecules responsible for coronary matrix remodeling in insulinresistant diabetic rats. Arterioscler. Thromb. Vasc. Biol., 23, pp. 2021-2026.
43. Daugherty, A., Manning, M. W. and Cassis, L. A. (2000) Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J. Clin. Invest., 105, pp. 1605-1612.
44. Grant, S. F., Thorleifsson, G., Reynisdottir, I., Benediktsson, R. and Manolescu, A. J.S. (2006) Variant of transcription factor 7-like 2 (TCF7L2). gene confers risk of type 2 diabetes. Nat. Genet., 38, pp. 320-323.
45. Janssens, A. C.J.W., Gwinn, M., Valdez, R., Naravan, K. M.V. and Khoury, M. J. (2006) Predictive genetic testing for type 2 diabetes. BMJ, 333, pp. 509-510.
46. Shimazaki, A., Kawamura, Y., Kanazawa, A., Sekine, A., Saito, S., Tsunoda, T. and Koya, D. (2005) Genetic variations in the gene encoding ELMO1 are associated with susceptibility to diabetic nephropathy. Diabetes, 54, pp. 1171-1178.
47. Astrand, H., Ryden-Ahlgren, A., Sundkvist, G., Sandgren, T. and Lanne, T. (2007) Reduced aortic wall stress in diabetes mellitus. Eur. J. Vasc. Endovasc. Surg., 33, pp. 592-598.
48. Sonesson, B., Hansen, F., Stale, H. and Lanne, T. (1993) Compliance and diameter in the human abdominal aorta-the influence of sex and age. Eur. J. Vasc. Surg., 7, pp. 690-697.
49. Lijnen, H. R. (2001) Plasmin and matrix metalloproteinases in vascular remodelling. Thromb. Haemost., 86, pp. 324-333.
50. Allaire, E., Hasenstab, D., Kenagy, R. D., Starcher, B., Clowes, M. M. and Clowes, A. W. (1998) Prevention of aneurysm development and rupture by local overexpression of plasminogen activator inhibitor-1. Circulation, 98, pp. 249-255.
51. Deng, G. G., Martin-McNulty, B., Sukovich, D. A., Freay, A., Halks-Miller, M., Thinnes, T., Luskutoff, D. J., Carmeleit, P., Dole, W. P. and Wang, Y.-X. (2003) Urokinase-type plasminogen activator plays a critical role in angiotensin II-induced abdominal aortic aneurysm. Circ. Res., 92, pp. 510-517.
52. Touat, Z., Ollivier, V., Dai, J., Huisse, M.-G., Bezeaud, A., Sebbag, U., Palombi, T., Rossignol, P., Meilhac, O., Guillin, M.-C. and Michel, J.-B. (2006) Renewal of mural thrombus releases plasma markers and is involved in aortic aneurysm evolution. Am. J. Path., 168, pp. 1022-1030.
53. Lindholt, J. S., Jorgensen, B., Fasting, H. and Henneberg, E. W. (2001) Plasma levels of plasmin-antiplasmin complexes are predictive for small andominal aortic aneurysms expanding to operation-recommendable sizes. J. Vasc. Surg., 34, pp. 611-615.
54. Rossaak, J. I., van Rij, A., Jones, J. T. and Harris, E. L. (2000) Association of G4/G5 polymorphism in the promoter region of plasminogen activator inhibitor-1 with abdominal aortic aneurysms. J. Vasc. Surg., 31, pp. 1026-1032.
55. Festa, A., D'Agostino Jr, R., Mykkanen, L., Tracey, R. P., Zaccaro, D. J., Hales, C. N. and Haffner, S. M. (1999) Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. Arterioscler. Thromb. Vasc. Biol., 19, pp. 562-568.
56. De Cosmo, S., Tassi, V., Thomas, S., Piras, G. P., Trevisan, R., Perin, P. Cavallo, Bacci, S., Zucaro, L., Cisternino, C., Trischitta, V. and Viberti, G. C. (2002) The Decorin gene 179 allelic variant is associated with a slower progression of renal disease in patients with type 1 diabetes. Nephron, 92, pp. 72-76.
57. Funk, M., Endler, G., Exner, M., Marculescu, R., Endler, L., Abrahamian, H., Mauler, H., Grimm, A., Raith, M., Mannhalter, C., Prager, R., Irsigler, K. and Wagner, O. F. (2005) PAI-1 4G/5G insertion/deletion promoter polymorphism and microvascular complications in type 2 diabetes mellitus. Wien Klin Wochenschr., 117, pp. 707-710.
58. Winlove, C. P., Parker, K. H., Avery, N. C. and Bailey, A. J. (1996) Interactions of elastin and aorta with sugars in vitro and their effects on biochemical and physical properties. Diabetologia, 39, pp. 1131-1139.
59. Aronson, D. (2003) Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J. Hyperten., 21, pp. 3-12.
60. Konova, E., Baydanoff, S., Atanasova, M. and Velkova, A. (2004) Age-related changes in the glycation of human aortic elastin. Exp. Gerontol., 39, pp. 249-254.
61. Schram, M. T., Henry, R. M.A., van Dijk, R. A.J.M., Kostense, P. J., Dekker, J. M., Nijpels, G., Heine, R. J. and Bouter, L. M. (2004) Increased central artery stiffness in impaired glucose metabolism and type 2 diabetes. The Hoorn Study. Hypertension, 43, pp. 176-181.
62. Rittie, L., Berton, A., Monboisse, J.-C., Hornebeck, W. and Gillery, P. (1999) Decreased contraction of glycated lattices coincides with impaired matrix metalloproteinase production. Biochem. Biophys. Res. Comm., 264, pp. 488-492.
63. Kuzuya, M., Asai, T., Kanda, S., Maeda, K., Cheng, X. and Iguchi, A. (2001) Glycation cross-links inhibit matrix metalloproteinase-2 activation in vascular smooth muscle cells cultured on collagen lattice. Diabetologia, 44, pp. 433-436.
64. Kim, Y. S., Kim, B. C., Song, C. Y., Hong, H. K., Moon, K. C. and Lee, H. S. (2001) Advanced glycosylation end products stimulate collagen mRNA synthesis in mesangial cells mediated by protein kinase C and transforming growth factor-beta. J. Lab. Clin. Med., 138, pp. 59-68.
65. Anderson, S., Wu, K., Nagase, H., Stettlet-Stevenson, W., Kim, Y. and Tsibary, E. (1996) Effect of matrix glycation on expression of Type IV collagen, MMP-2, MMP-9 and TIMP-1 by human mesangial cells. Cell Adhes. Commun., 4, pp. 89-101.
66. Shimizu, K., Mitchell, R. N. and Libby, P. (2006) Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler. Thromb. Vasc. Biol., 26, pp. 987-994.
67. Fogelstrand, L., Hulthe, J., Hulten, L. M., Wiklund, O. and Fagerberg, B. (2004) Monocytic expression of CD14 and CD18, circulating adhesion molecules and inflammatory markers in women with diabetes mellitus and impaired glucose tolerance. Diabetologia, 47, pp. 1948-1952.
68. Ziegler, D. (2005) Type 2 diabetes as an inflammatory cardiovascular disorder. Curr. Mol. Med., 5, pp. 309-322.
69. Marfella, R., D'Amico, M., Esposito, K., Baldi, A., Filippo, C. Di, Siniscalchi, M. and Sasso, F. C. (2006) The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: Effects of rosiglitazone treatment. Diabetes Care, 55, pp. 622-632.
70. Burke, A. P., Kolodgie, F. D., Zieske, A., Fowler, D. R., Weber, D. K., Varghese, P. J., Farb, A. and Virmani, R. (2004) Morphologic findings of coronary atherosclerotic plaques in diabetics: A postmortem study. Arterioscler. Thromb. Vasc. Biol., 24, pp. 1266-1271.
71. Cipollone, F., Iezzi, A., Fazia, M., Zucchelli, M., Pini, B., Cuccurullo, C., De Cesare, D. and De Blasis, G. (2003) The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: Role of glycemic control. Circulation, 108, pp. 1070-1077.
72. Viardot, A., Grey, S. T., Mackay, F. and Chisholm, D. (2007) Potential anti-inflammatory role of insulin via the preferential polarization of effector T cells towards a T-helper 2 phenotype. Endocrinology, 148, pp. 346-353.
73. McGrath, J. C., Deighan, C., Briones, A. M., Shafaroudi, M. M., McBride, M., Adler, J., Arribas, S. M., Vila, E. and Daly, C. (2005) New aspects of vascular remodelling: The involvement of all vascular cell types. Exp. Physiol., 90, pp. 469-475.
74. Wesley, R. N., Meng, X., Godin, D. and Galis, Z. S. (1998) Extracellular matrix modulates macrophage functions characteristic to atheroma: collagen type I enhances acquisition of resident macrophage traits by human peripheral blood monocytes in vitro. Arterioscler. Thromb. Vasc. Biol., 18, pp. 432-440.
75. Lepidi, S., Kenagy, R. D., Raines, E. W., Chiu, E. S., Chait, A., Ross, R. and Clowes, A. W. (2001) MMP9 production by human monocyte-derived macrophages is decreased on polymerized type I collagen. J. Vasc. Surg., 34, pp. 1111-1118.
76. Soldatos, G. and Cooper, M. E. (2006) Advanced glycation end products and vascular structure and function. Curr. Hypertens. Rep., 8, pp. 472-478.
77. Costa, J., Borges, M., David, C. and Carneiro, A. Vaz (2006) Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ, 332, pp. 1115-1124.
78. Schouten, O., van Laanen, J. H.H. and Boersma, E. (2006) Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur. J. Vasc. Endovasc. Surg., 32, pp. 21-26.
79. Lewis, E. J., Hunsicker, L. G., Bain, R. P. and Rohde, R. D. (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Eng. J. Med., 329, pp. 1456-1462.
80. Lit, Y. Z. and Meyer, T. (2006) Managing diabetic nephropathy: Recent studies. Curr. Opin. Nephrol. Hypertens., 15, pp. 111-116.
81. Liao, S., Miralles, M., Kelley, B. J., Curci, J. A., Borhani, M. and Thompson, R. W. (2001) Suppression of experimental abdominal aneurysms by treatment with angiotensin-converting enzyme inhibitors. J. Vasc. Surg., 33, pp. 1057-1064.
82. Hackam, D. G., Thiruchelvam, D. and Redelmeier, D. A. (2006) Angiotensin-converting enzyme inhibitors and aortic rupture: A population-based case-control study. Lancet, 368, pp. 659-665.
83. Rizzoni, D., Porteri, E., De Ciuceis, C., Sleiman, I., Rodella, L., Rezzani, R., Paiardi, S., Bianchi, R., Ruggeri, G., Boari, G. E., Muiesan, M. L., Salvetti, M., Zani, F., Miclini, M. and Rosei, E. A. (2005) Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus. Hypertension, 45, pp. 659-665.
84. Jandeleit-Dahm, K. A., Lassila, M. and Allen, T. J. (2005) Advanced glycation end products in diabetes-associated atherosclerosis and renal disease: Interventional studies. Ann. NY Acad. Sci., 1043, pp. 759-766.
85. Bakris, G. L., Bank, A. J., Kass, D. A., Neutel, J. M., Preston, R. A. and Oparil, S. (2004) Advanced glycation end-product cross-link breakers. Am. J. Hypertens., 17, pp. 23S-30S.
86. Giannico, G., Cortes, P., Baccora, M. H., Hassett, C., Taube, D. W. and Yee, J. (2007) Glibenclamide prevents increased extracellular matrix formation induced by high glucose concentration in mesangial cells. Am. J. Physiol. Renal. Physiol., 292, pp. F57-F65.
87. Fukui, D., Miyagawa, S., Soeda, J., Tanaka, J., Urayama, H. and Kawasaki, S. (2003) Overexpression of transforming growth factor β1 in smooth muscle cells of human abdominal aortic aneurysm. Eur. J. Vasc. Endovas. Surg., 25, pp. 540-545.
88. McLennan, S., Fisher, E., Martell, S., Death, A., Williams, P., Lyons, J. and Yue, D. (2000) Effects of glucose on matrix metalloproteinase and plasmin activities in mesangial cells: Possible role in diabetic nephropathy. Kidney Int., 58, pp. S81-S87.
89. McLennan, S. V., Martell, S. Y.K. and Yue, D. K. (2000) High glucose concentration inhibits the expression of membrane type metalloproteinase by mesangial cells: Possible role in mesangium accumulation. Diabetologia, 43, pp. 642-648.